investor harm

Class action lawsuit filed against REGENXBIO alleging false statements about RGX-111 gene therapy development and clinical trials, covering investors from February 2022 through January 2026.

Masonite faces class action alleging it failed to disclose Owens Corning acquisition offers while repurchasing stock at depressed prices from June 2023 to February 2024.

Law firm files class action against Kyndryl for alleged securities fraud, false financial statements, and internal control failures affecting investors from August 2024 through February 2026.

Class action filed against Lakeland Industries alleging executives misrepresented Pacific Helmets and Jolly business performance while concealing operational issues from December 2023 through December 2025.

$PLUG faces class action lawsuit alleging false statements about DOE funding and hydrogen production facilities. Investors can seek lead plaintiff status by April 3, 2026.

Class action lawsuit alleges Boston Scientific made false statements about U.S. electrophysiology segment sustainability, citing undisclosed competitive pressures and regulatory headwinds affecting procedure volumes.

BellRing Brands faces class action lawsuit alleging materially false sales statements driven by temporary customer inventory rebuilding, not genuine demand.

Class action lawsuit filed against $TCOM alleging false statements on regulatory risks from monopolistic practices during April 2024-January 2026 period.

Class action lawsuit filed against $EOS alleging securities fraud over undisclosed production delays, quality control issues, and inadequate guidance during Nov 2025-Feb 2026 period.

Class action lawsuit filed against $AMC alleging securities fraud over APE preferred equity units and undisclosed dividend exclusion loophole.

Class action lawsuit alleges monday.com made false statements about revenue growth and sales cycles between September 2025 and February 2026, claiming investor harm.

Class action lawsuit filed against Corcept Therapeutics alleges material misstatements about relacorilant drug trials and regulatory approval prospects, covering investors from October 2024 through December 2025.

Class action filed against NYSE-listed ChowChow Cloud alleging securities fraud involving market manipulation, social media misinformation, and undisclosed trading suspension risks for investors during September-December 2025.

Class action lawsuit filed against $SNOW alleging securities fraud over concealed product changes and CEO departure rumors during June 2023-February 2024 period.

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC. Investors from June 2023-December 2025 eligible; lead plaintiff deadline April 2026.

Securities fraud lawsuit filed against $DRVN alleging false financial statements, weak controls, and revenue overstatement from May 2023 through February 2026.

Class action lawsuit filed against Nektar Therapeutics alleging materially false statements regarding REZOLVE-AA trial enrollment protocols, claiming compromised trial integrity.

Class action filed against $METC alleging executives made false statements about Brook Mine development progress. Investors who purchased securities July-October 2025 may be eligible.

Class action lawsuit filed against $REGENXBIO alleging false statements on RGX-111 gene therapy. Covers investors from February 2022 to January 2026.

Class action lawsuit filed against $ORCL alleging executives misrepresented AI infrastructure spending impact. Claims massive CapEx won't yield equivalent near-term revenue growth.